GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Quick Ratio

CNSP (CNS Pharmaceuticals) Quick Ratio : 1.82 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. CNS Pharmaceuticals's quick ratio for the quarter that ended in Sep. 2024 was 1.82.

CNS Pharmaceuticals has a quick ratio of 1.82. It generally indicates good short-term financial strength.

The historical rank and industry rank for CNS Pharmaceuticals's Quick Ratio or its related term are showing as below:

CNSP' s Quick Ratio Range Over the Past 10 Years
Min: 0.26   Med: 2.88   Max: 25.38
Current: 1.82

During the past 7 years, CNS Pharmaceuticals's highest Quick Ratio was 25.38. The lowest was 0.26. And the median was 2.88.

CNSP's Quick Ratio is ranked worse than
66.4% of 1503 companies
in the Biotechnology industry
Industry Median: 3.41 vs CNSP: 1.82

CNS Pharmaceuticals Quick Ratio Historical Data

The historical data trend for CNS Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNS Pharmaceuticals Quick Ratio Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 25.38 8.13 2.88 2.55 0.26

CNS Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.26 0.26 0.32 1.82

Competitive Comparison of CNS Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, CNS Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNS Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's Quick Ratio falls into.



CNS Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

CNS Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.591-0)/6.133
=0.26

CNS Pharmaceuticals's Quick Ratio for the quarter that ended in Sep. 2024 is calculated as

Quick Ratio (Q: Sep. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(7.388-0)/4.057
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNS Pharmaceuticals  (NAS:CNSP) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


CNS Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CNS Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Executives
Christopher Downs officer: Chief Financial Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco director, officer: Chief Executive Officer PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes director 13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke director C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027